Short Sellers, No Direction in Biotech (AMGN, BIIB, CELG, GENZ, GILD)

Posted: December 10, 2008 at 11:04 am

It seems that short sellers have no real direction in the major NASDAQ biotech stocks from mid-November to late-November.  Generally you see a pattern.  This month the only pattern seems to be one of no conviction either way.  Here are the short seller reports in the short interest:

Stock (Ticker)                         NOV. 28      NOV. 14      CHANGE
Amgen Inc. (AMGN)               23,033,081   24,169,278    -4.70%
Celgene Corporation (CELG)    8,298,820    8,040,642     +3.21%
Biogen Idec Inc. (BIIB)             8,027,848    7,938,637     +1.12%
Genzyme Corporation (GENZ)  6,569,181    6,797,501     -3.36%
Gilead Sciences (GILD)           29,055,791  30,213,915    -3.83%

Jon C. Ogg
December 10, 2008

Read more: Biotech, Short Interest, , , , ,
    • Featured Article:

    The 15 CEOs Who Should Be Paid $1 A Year

    Lee Iacocca, Chrysler’s CEO in 1979, worked for $1 a year while his company paid back taxpayers $1.2 billion in loan guarantees. Edward Liddy, former CEO of Allstate (ALL) was paid $1 a year when he stepped in to run the crumbling AIG (AIG) as the request of Henry Paulson, who was Treasury Secretary at [...]

    Read Full Story »
    Pages: 1 2 3 4